Global Synthesis Polypeptide Drugs Market Size By Type (Immunity Regulating Medicine (Allergy Infection and Immune), Digestive System Drugs (Gastrointestinal Type)), By Application (Gene Delivery, Dru...

The Global Synthesis Polypeptide Drugs Market was valued at USD 12.3 billion in 2023 and is projected to reach USD 22.6 billion by 2031, growing at a CAGR of 7.8% during the forecast period from 2023 to 2031. The market growth is primarily driven by increasing prevalence of chronic diseases, rising demand for targeted therapeutics, and advancements in peptide synthesis technologies. Synthetic polypeptide drugs, known for their high specificity and safety profile, are being increasingly adopted in the treatment of cancer, metabolic disorders, infectious diseases, and rare conditions.

Drivers:

1. Rising Incidence of Chronic and Lifestyle Diseases:

The increasing global burden of diseases such as cancer, diabetes, and cardiovascular disorders is driving the need for targeted and effective therapeutic options. Synthetic polypeptide drugs are becoming a preferred choice due to their precision and reduced side effects.

2. Technological Advancements in Drug Synthesis:

Improvements in peptide synthesis techniques, such as solid-phase synthesis and recombinant technology, have enhanced production efficiency, yield, and scalability, contributing to market expansion.

3. Expanding Biopharmaceutical R&D Investment:

Growing investments by pharmaceutical and biotech companies in research and development of biologics and peptide-based drugs are bolstering market demand.

Restraints:

1. High Manufacturing and Regulatory Compliance Costs:

Synthesis of polypeptide drugs involves complex processes and stringent regulatory requirements, which increase production costs and hinder market entry for smaller firms.

2. Limited Oral Bioavailability of Peptide Drugs:

Many synthetic peptides have poor oral bioavailability and require parenteral administration, which can limit patient compliance and market adoption.

Opportunity:

1. Development of Novel Drug Delivery Systems:

Emerging drug delivery technologies such as nanoparticle-based carriers and oral peptide formulations are opening new avenues for enhancing peptide drug efficacy and market reach.

2. Growing Market in Emerging Economies:

Rising healthcare infrastructure and growing pharmaceutical investments in countries like India, China, and Brazil provide untapped potential for market growth.

Market by System Type Insights:

By system type, the Long-acting Synthetic Polypeptides segment held the dominant market share in 2023. These formulations reduce dosing frequency and improve patient adherence, especially in chronic conditions such as diabetes and hormone disorders. The Modified-release Synthetic Polypeptides segment is anticipated to exhibit the highest CAGR, fueled by continuous innovation in controlled drug delivery technologies.

Market by End-use Insights:

The Hospital Pharmacy segment was the largest revenue generator in 2023, supported by high prescription rates and the increasing use of peptide drugs in specialized clinical settings. The Retail Pharmacy segment is projected to witness robust growth due to expanding access to specialty drugs and enhanced healthcare delivery in outpatient settings.

Market by Regional Insights:

North America led the global synthesis polypeptide drugs market in 2023, driven by advanced healthcare infrastructure, robust R&D activity, and favorable reimbursement frameworks. Asia-Pacific is expected to grow at the fastest rate during the forecast period, owing to increasing healthcare investments, rising chronic disease prevalence, and a growing biopharma sector in nations such as China, India, and South Korea.

Competitive Scenario:

Key market players include Ipsen Pharma, Eli Lilly and Company, Novo Nordisk, Sanofi, Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Bachem Holding AG, CordenPharma, and PolyPeptide Group. These companies focus on strategic alliances, technological innovation, and product portfolio expansion to strengthen their market positions.

Key Market Developments:

2023: Eli Lilly announced expanded access programs for its synthetic GLP-1 receptor agonists targeting type 2 diabetes and obesity.

2024: PolyPeptide Group introduced a new solid-phase synthesis platform aimed at cost-efficient production of therapeutic peptides.

2025: Amgen initiated clinical trials for a novel synthetic polypeptide targeting advanced-stage prostate cancer, highlighting innovation in oncology peptides.

Scope of Work – Global Synthesis Polypeptide Drugs Market

FAQs:

1) What is the current market size of the Global Synthesis Polypeptide Drugs Market?

The market size was valued at USD 12.3 billion in 2023.

2) What is the major growth driver of the Global Synthesis Polypeptide Drugs Market?

The major growth driver is the increasing demand for targeted therapeutics due to the rising prevalence of chronic diseases.

3) Which is the largest region during the forecast period in the Global Synthesis Polypeptide Drugs Market?

North America is expected to remain the largest region during the forecast period.

4) Which segment accounted for the largest market share in the Global Synthesis Polypeptide Drugs Market?

The Long-acting Synthetic Polypeptides segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Synthesis Polypeptide Drugs Market?

Key players include Ipsen Pharma, Eli Lilly, Novo Nordisk, Sanofi, Pfizer, Amgen, Teva, Bachem, CordenPharma, and PolyPeptide Group.